Table 1 Summary of key assumptions considered in the cost-effectiveness model

Model structure

Two-stage Markov cohort model

CE model time horizon

Lifetime

Model cycle

Monthly

CV mortality for SoC

SHIFT data by applying Gompertz survival model

HR for CV mortality of ivabradine vs SoC

0.90 (0.80 – 1.03) based on SHIFT data

Rate hospitalization

SHIFT data by applying Poisson model

Rate ratio for hospitalization of ivabradine vs SoC

0.83 (0.78 – 0.93) based on SHIFT data

Length of hospitalization

Local data (based on experts’ opinion)

Utility data

SHIFT data by applying mixed regression model

NYHA data

SHIFT data by applying adjusted ordered logistic regression

Ivabradine treatment effect

Cardiovascular endpoint

Ivabradine use (years)

Lifelong

Cost discount rate per annum

3.5%

Effects discount rate per annum

3.5%

Resource utilization and unit costs

Local data (government gazette and experts’ opinion)

Outcome mesaures

QALYs, LYs, ICER per QALY and per LY gained, lifetime total cost